First Manhattan CO Editas Medicine, Inc. Transaction History

First Manhattan CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$6.25 - $11.11 $2,500 - $4,444	-400 Reduced 90.29%	43 $0
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $1,408 - $2,763	100 Added 29.15%	443 $8,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $2,655 - $4,057	100 Added 41.15%	343 $9,000
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $1,688 - $3,136	43 Added 21.5%	243 $9,000
Q1 2020 May 06, 2020	BUY	$14.88 - $32.78 $2,976 - $6,556	200 New	200 $3,000

244

56.8M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.